Appearing as a noteworthy breakthrough in the struggle against obesity, this medication is capturing considerable interest . This treatment combines properties of two recognized GLP-1 receptor agonists, liraglutide, and an additional glucose-dependent hormonal component. Initial clinical results have indicated significant fat reduction in patients